LATS1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL81844	0.41	5/20
SCHEMBL83123	0.41	5/20
SCHEMBL115485	0.37	5/20
SCHEMBL83998	0.36	5/20
SCHEMBL513496	0.36	3/20
SCHEMBL513497	0.36	3/20
SCHEMBL218367	0.36	3/20
SCHEMBL250475	0.36	3/20
Capivasertib (SCHEMBL390243)	1.00	2/20
Capivasertib (SCHEMBL390244)	1.00	2/20
Capivasertib (SCHEMBL391382)	1.00	2/20
SCHEMBL386619	0.90	2/20
SCHEMBL386620	0.90	2/20
SCHEMBL390401	0.90	2/20
SCHEMBL391567	0.87	2/20
SCHEMBL393210	0.87	2/20
SCHEMBL391511	0.84	2/20
SCHEMBL391512	0.84	2/20
SCHEMBL386843	0.84	2/20
SCHEMBL386844	0.84	2/20

Clinical trials — most relevant to LATS1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Doxycycline In Lymphangioleiomyomatosis (LAM)	PHASE4	COMPLETED
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib	PHASE2	COMPLETED
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer	PHASE2	COMPLETED
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI	PHASE2	COMPLETED
Feasibility of [11C]Acetate-PET in LAM and TSC	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)	PHASE1/PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma	PHASE1/PHASE2	COMPLETED
SCARFREE-001: Verteporfin for Scar Prevention	PHASE2	NOT_YET_RECRUITING
Temsirolimus as Second-line Therapy in HCC	PHASE2	UNKNOWN
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer	PHASE1	WITHDRAWN
Glutamine Supplementation in People With Immune Dysregulation	EARLY_PHASE1	WITHDRAWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Muscle Regrowth During Physical Rehabilitation and Amino Acid Supplementation	nan	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.	nan	COMPLETED
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Investigation of an Amino Acid Supplement on Glucose Levels in Obese Subjects	nan	COMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore	nan	COMPLETED
IVM for Patients With Low Ovarian Response. Does it Improve IVFoutcomes and Does it Improve the Following IVF Cycle?	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a LATS1 binder may also engage these)

Protein	Name	Similarity
Q8BYR2	—	1.000	Q8BYR2 →
BMP2K	BMP-2-inducible protein kinase	0.995	landscape →
Q6E3D4	—	0.994	Q6E3D4 →
P24610	—	0.994	P24610 →
CDKL5	Cyclin-dependent kinase-like 5	0.994	landscape →
Q9NRR4	—	0.993	Q9NRR4 →
P46200	—	0.993	P46200 →
Q86TC9	—	0.993	Q86TC9 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.993	landscape →
Q8STF6	—	0.993	Q8STF6 →
Q5HZJ0	—	0.993	Q5HZJ0 →
Q1L8J7	—	0.993	Q1L8J7 →
Q3YC04	—	0.993	Q3YC04 →
Q91904	—	0.993	Q91904 →
Q8VII8	—	0.993	Q8VII8 →
P06537	—	0.993	P06537 →
P97868	—	0.992	P97868 →
Q0WPH8	—	0.992	Q0WPH8 →
Q80TZ9	—	0.992	Q80TZ9 →
Q7TN99	—	0.992	Q7TN99 →
P57682	—	0.992	P57682 →
Q4JM28	—	0.992	Q4JM28 →
O45797	—	0.992	O45797 →
Q9XTT4	—	0.992	Q9XTT4 →
G5EFF5	—	0.992	G5EFF5 →
P06536	—	0.992	P06536 →
Q8C0I4	—	0.992	Q8C0I4 →
Q5R8X7	—	0.992	Q5R8X7 →
O17087	—	0.992	O17087 →
A7MBB4	—	0.992	A7MBB4 →